July 4th, 2016 | Vol. 188, No. 1 | U.S.
Hannah Whitaker for TIME| TIME
Jennifer Doudna tells TIME what it was like to find out she'd been awarded a Novel Prize for her work describing CRISPR gene editing tech.| TIME
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems provide bacteria and archaea with adaptive immunity against viruses and plasmids by using CRISPR RNAs (crRNAs) to guide the silencing of invading nucleic acids. We show here that in a subset of these s …| PubMed
- First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the βS/βS, βS/β+ or βS/β0 genotype, for whom hematopoietic| CRISPR Therapeutics
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.| U.S. Food and Drug Administration
